Respivant Sciences Overview
Pro stress-test →Respivant Sciences is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of patients suffering from respiratory diseases. The company's lead candidate, RVT-1601, is a mast cell stabilizer with pleotropic immune modulating activity delivered via oral inhalation using a proprietary electronic nebulizer device. The company is a subsidiary of Roivant Sciences (September 2018 launch).
Strategic Profile
Pro stress-test →A Phase 2a clinical trial was completed with positive results in IPF patients with chronic cough, an orphan disease with no curative therapy, and a robust Phase 2b study has been initiated for this often-debilitating condition. The company is led by experienced respiratory drug developers with prior exits including Elevation Pharmaceuticals (acquired 2012) and Patara Pharma. However, Respivant is a deadpooled company and is not active anymore.
Competitive Landscape
Pro stress-test →Respivant competed in orphan respiratory disease and IPF chronic cough space against companies like aTyr Pharma, ReCode Therapeutics, and other respiratory/pulmonary fibrosis-focused developers. The narrow orphan indication limited market size and likely contributed to funding constraints. Larger pharma and well-funded biotech competitors have broader resources and patient access.
Industry Context
Respivant Sciences operates in Orphan respiratory disease therapeutics.
Key facts
Founded: 2018 · Headquarters: San Diego, US · Employees: Unknown · Revenue: N/A · Market cap: N/A